Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smoother sailing in China?

This article was originally published in The Gray Sheet

Executive Summary

The Chinese government's pledge to take action by the end of May to eliminate duplicative testing and inspection requirements would help streamline its medical technology registration process, AdvaMed says April 12. The agreement emerged from the 17th annual senior-level meeting of the Joint Commission on Commerce & Trade, concluded April 11 in Washington, D.C. Though testing required separately by China's State Food & Drug Administration and its General Administration of Quality, Supervision, Inspection & Quarantine is intended to focus on efficacy and safety, respectively, industry has noted that the tests can be redundant (1"The Gray Sheet" March 14, 2005, p. 25)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel